SCS
SCS operates in Biotechnology.
SCS (SCS) - Net Assets
Latest net assets as of June 2024: zł7.17 Million PLN
Based on the latest financial reports, SCS (SCS) has net assets worth zł7.17 Million PLN as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł12.92 Million) and total liabilities (zł5.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł7.17 Million |
| % of Total Assets | 55.47% |
| Annual Growth Rate | 4.96% |
| 5-Year Change | -21.68% |
| 10-Year Change | N/A |
| Growth Volatility | 35.39 |
SCS - Net Assets Trend (2015–2023)
This chart illustrates how SCS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SCS (2015–2023)
The table below shows the annual net assets of SCS from 2015 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | zł7.43 Million | -2.04% |
| 2022-12-31 | zł7.58 Million | +0.35% |
| 2021-12-31 | zł7.55 Million | -1.66% |
| 2020-12-31 | zł7.68 Million | -18.99% |
| 2019-12-31 | zł9.48 Million | -7.09% |
| 2018-12-31 | zł10.21 Million | +101.19% |
| 2017-12-31 | zł5.07 Million | +3.18% |
| 2016-12-31 | zł4.92 Million | -2.46% |
| 2015-12-31 | zł5.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SCS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 224.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | zł7.58 Million | 102.08% |
| Total Equity | zł7.43 Million | 100.00% |
SCS Competitors by Market Cap
The table below lists competitors of SCS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cupani Metals Corp.
PINK:ICPLF
|
$990.50 |
|
MEDCO ENERGI INTL
MU:MEF
|
$991.06 |
|
FVE
WAR:FVE
|
$991.52 |
|
Fiske PLC
LSE:FKE
|
$993.15 |
|
BORDERS & SOUTH PET
BE:B5T
|
$989.74 |
|
Universal Global Hub Inc
PINK:UGHB
|
$989.05 |
|
Millennium Investment & Acquisition Company Inc
PINK:MILC
|
$988.99 |
|
IXICO PLC
LSE:IXI
|
$986.57 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 7,581,403 to 7,427,056, a change of -154,347 (-2.0%).
- Net loss of 154,347 reduced equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-154.35K | -2.08% |
| Other Changes | zł-0.00 | -0.0% |
| Total Change | zł- | -2.04% |
Book Value vs Market Value Analysis
This analysis compares SCS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | zł0.19 | zł0.42 | x |
| 2021-12-31 | zł0.18 | zł0.42 | x |
| 2022-12-31 | zł0.18 | zł0.42 | x |
| 2023-12-31 | zł0.18 | zł0.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SCS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -36.81%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.83x
- Recent ROE (-2.08%) is below the historical average (0.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 2.46% | 17.40% | 0.03x | 4.18x | zł-380.10K |
| 2016 | 15.18% | 39.65% | 0.09x | 4.30x | zł254.72K |
| 2017 | 0.64% | 7.40% | 0.02x | 4.19x | zł-475.06K |
| 2018 | -5.11% | -99.50% | 0.03x | 1.88x | zł-1.54 Million |
| 2019 | -7.63% | -124.22% | 0.03x | 1.82x | zł-1.67 Million |
| 2020 | 0.08% | 2.39% | 0.02x | 1.93x | zł-761.81K |
| 2021 | -1.69% | -24.23% | 0.03x | 2.26x | zł-882.89K |
| 2022 | 0.35% | 10.74% | 0.02x | 1.95x | zł-731.53K |
| 2023 | -2.08% | -36.81% | 0.03x | 1.83x | zł-897.05K |
Industry Comparison
This section compares SCS's net assets metrics with peer companies in the Biotechnology & Medical Research industry.
Industry Context
- Industry: Biotechnology & Medical Research
- Average net assets among peers: $3,240,690
- Average return on equity (ROE) among peers: -2.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCS (SCS) | zł7.17 Million | 2.46% | 0.80x | $990.09 |
| Readgene (RDG) | $3.24 Million | -2.36% | 3.67x | $13.00K |